Overactive bladder comprises a spectrum of conditions ranging from urgency-frequency syndrome to urge incontinence. The incidence of overactive bladder increases with age, with a prevalence exceeding 4% to 5.5% of the population. Its etiology is not clearly understood, and the treatment options often have poor efficacy and significant side effects.
Dosing commences in phase 1/2 trial of AB-2100 in ccRCC
May 15th 2024The dose escalation/dose expansion study is evaluating the safety and efficacy of AB-2100 in patients with ccRCC who either came back or did not improve following prior treatment with a checkpoint inhibitor and a VEGF inhibitor.